Thryv Therapeutics Targets LQTS with THRV-1268 Trial Launch

San Francisco, California, USA – April 22, 2026

In a significant advancement for rare cardiac disease therapeutics, Thryv Therapeutics has announced the initiation of patient dosing in its Phase 2/3 Wave II clinical trial evaluating THRV-1268 for genetically confirmed Long QT Syndrome (LQTS) Type 2, alongside receiving U.S. FDA Fast Track Designation for both LQTS Type 2 and Type 3. This dual milestone underscores the growing momentum behind precision medicine approaches targeting inherited arrhythmias, offering new hope for patients with limited treatment options.

Phase 2/3 Wave II Study Targets Genetic LQTS

The Wave II clinical study represents a multicenter, Phase 2/3 trial designed to evaluate the safety, efficacy, and tolerability of THRV-1268 in patients with genetically confirmed Long QT Syndrome Type 2. Enrollment is actively progressing across leading inherited arrhythmia centers in the United States, with initial patient dosing already underway.

The trial’s primary endpoint focuses on QTc interval reduction (QTcF) over a six-hour measurement window, a critical biomarker directly associated with arrhythmic risk and sudden cardiac events. Secondary assessments include cardiac rhythm stability, safety outcomes, and tolerability, providing a comprehensive evaluation of therapeutic impact.

Patients enrolled in the study will initially receive an oral suspension formulation for 12 weeks, enabling early data generation for pediatric applications, followed by the option to transition to a tablet formulation for extended treatment up to one year. This flexible design highlights the company’s strategy to address both adult and pediatric patient populations, a key unmet need in rare genetic cardiac disorders.

Early-stage research suggests that serum glucocorticoid inducible kinase 1 (SGK1) plays a crucial role in cardiac electrophysiology, positioning THRV-1268 as a potential first-in-class disease-modifying therapy that directly targets the underlying biology of LQTS rather than just managing symptoms.

FDA Fast Track Designation Accelerates Development

The FDA Fast Track Designation granted to THRV-1268 marks a critical regulatory milestone, recognizing the therapy’s potential to address a serious and life-threatening condition with significant unmet medical need. This designation enables enhanced regulatory interaction, including more frequent communication with the FDA and eligibility for Rolling Review, Priority Review, and Accelerated Approval pathways.

For patients with LQTS, particularly Types 2 and 3, current treatment options are limited and often focus on symptom management rather than disease modification. The Fast Track status reinforces confidence in THRV-1268’s potential to deliver clinically meaningful improvements in QT interval normalization and arrhythmic risk reduction.

Importantly, this designation also reflects increasing regulatory support for genetically targeted therapies, aligning with broader trends in precision medicine where treatments are tailored to specific molecular and genetic profiles. As a result, THRV-1268 is positioned within a new generation of therapies aiming to transform the standard of care in inherited cardiac disorders.

Transforming the Future of Inherited Cardiac Care

Long QT Syndrome is a rare but potentially fatal genetic condition characterized by prolonged cardiac repolarization, leading to irregular heart rhythms, syncope, and sudden cardiac death. Patients and families often face lifelong disease management challenges, including medication adherence, lifestyle restrictions, and ongoing monitoring.

Thryv Therapeutics’ approach represents a paradigm shift from symptom control to disease modification, targeting the root electrophysiological mechanisms responsible for QT prolongation. By focusing on SGK1 inhibition, THRV-1268 has the potential to deliver more durable and precise therapeutic outcomes, reducing both clinical and emotional burdens associated with the disease.

The company anticipates delivering initial clinical data in the fourth quarter of 2026, which will be pivotal in determining the therapy’s future regulatory and commercial trajectory. If successful, THRV-1268 could become the first targeted therapy specifically designed for genetically defined LQTS populations, addressing a long-standing gap in cardiovascular medicine.

As innovation in rare disease therapeutics accelerates, Thryv’s progress highlights the growing importance of targeted, mechanism-driven drug development, offering renewed optimism for patients living with life-threatening inherited arrhythmias.

Source: Thryv Therapeutics press release